A study in the journal Pediatrics evaluated the efficacy of primary BNT162b2, mRNA-1273, and heterologous mRNA Covid-19 vaccines in preventing hospitalization amongst adolescents in Sweden, Norway, Finland, and Denmark. It found that vaccine effectiveness against hospitalization ranged from 73% to 86% at six months, with the protection remaining consistent up to a year, including during the Omicron wave.
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
